REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
REGENXBIO Inc. (Nasdaq: RGNX) priced an underwritten public offering of 10,003,889 shares at $9.00 each and 1,111,111 pre-funded warrants at $8.9999 per warrant. Gross proceeds are expected at about $100.0 million before discounts and commissions. The deal is expected to close July 20, 2026, with a 30-day option for 1,667,250 more shares.
How this was made
The 30-second read
Why it matters
The priced offering increases share count risk (common stock plus pre-funded warrants) and can weigh on the stock until the market prices in dilution and the capital use plan.
Market read
A priced equity raise with a defined close date is a concrete, time-sensitive catalyst that can drive trading around dilution expectations.
What to watch
Watch for how the company intends to use proceeds, any concurrent guidance/clinical milestones, and whether the over-allotment option signals strong demand from underwriters.
Background
REGENXBIO announced the pricing terms for an underwritten public offering under an already-effective S-3 registration statement.
Ticker impact
REGENXBIO priced an underwritten public offering of 10,003,889 shares at $9.00 plus 1,111,111 pre-funded warrants at $8.9999.
Near-term downside bias on dilution/financing overhang, with potential stabilization after deal details are digested.
The article discloses a priced common stock and pre-funded warrant offering with expected ~$100M gross proceeds and a 30-day over-allotment option, which typically creates immediate supply/dilution concerns for the issuer’s shares.
Market effects
Adds to the biotech financing tape, reinforcing that gene-therapy developers may rely on equity issuance to fund late-stage catalysts.
Primarily impacts US small/mid-cap biotech sentiment and Nasdaq liquidity.
Limited direct global read-across, but contributes to broader risk appetite for pre-commercial biotech funding.
Counterpoint
If investors believe the company needs capital to de-risk late-stage trials, the offering could be viewed as reducing balance-sheet risk rather than purely dilutive.
Key entities
- issuerREGENXBIO Inc.
Nasdaq-listed gene therapy company that priced a $100M gross equity offering plus pre-funded warrants.
- underwriterMorgan Stanley
Joint book-running manager for the offering.
- underwriterJ.P. Morgan
Joint book-running manager for the offering.
- underwriterLeerink Partners
Joint book-running manager for the offering.
- underwriterMizuho
Joint book-running manager for the offering.
